Apremilast

Oral thalidomide analogue(phosphodiesterase 4 inhibitor) developed by Celegene for the indications spondylitis, psoriatic arthritis and psoriasis arthropathica as well as moderate to severe psoriasis vulgaris (S3 guideline). A small monocentric study is available for the lichen planus. Others for Behcet's disease, rheumatoid arthritis and atopic eczema. In the phase III study (ESTEEM) patients with moderate to severe psoriasis were treated with 2x30mg/day apremilast for 52 weeks. At week 16, 28.8% of those treated achieved a PASI-75 response (5.8% on placebo).

Good results can be achieved with 2x30mg/day apremilast in psoriasis capitis as well as in psoriasis of the nail (LAPIS-PSO study - cited after Reich K et al. 2016/2018).

Moderate to severe psoriasis vulgaris and psoriatic arthritis. Apremilast was approved in mid-January 2015.

see also under folliculitis decalvans

Diarrhoea, nausea, headache, upper respiratory tract infections.

Otezla (Celgene)

1. De Souza A et al (2012) Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol 11:1224-1226
2. Gottlieb AB et al (2008) An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin 24:1529-1538.
3. Paul J et al (2012) An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: A case series. J Am Acad Dermatol PubMed PMID: 22910104.
4. Reich K et al (2016) Annual Meeting of the Austrian Society of Dermatology and Venereology (ÖGDV), Vienna, lecture FV 10
5. Reich K et al (2018) Annual Meeting of the American Academy of Dermatology(AAD), February 18-20, 2018, San Diego , USA, Poster 7104
6. Samrao A et al (2012) A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 148:890-897